CD22 and leukemia: The SPDP-based immuno-RNases meditated a dose-dependent cytotoxicity towards targeted CD22-positive tumor cells (Figures 5(a) and 5(b)) but not towards the CD22-negative leukemia cells (Figure 5(c)).